WO2017083716A3 - Détermination de partenaires létaux synthétiques de modifications spécifiques du cancer et procédés pour les utiliser - Google Patents

Détermination de partenaires létaux synthétiques de modifications spécifiques du cancer et procédés pour les utiliser Download PDF

Info

Publication number
WO2017083716A3
WO2017083716A3 PCT/US2016/061623 US2016061623W WO2017083716A3 WO 2017083716 A3 WO2017083716 A3 WO 2017083716A3 US 2016061623 W US2016061623 W US 2016061623W WO 2017083716 A3 WO2017083716 A3 WO 2017083716A3
Authority
WO
WIPO (PCT)
Prior art keywords
partners
mutation
synthetic lethal
methods
cancer
Prior art date
Application number
PCT/US2016/061623
Other languages
English (en)
Other versions
WO2017083716A2 (fr
Inventor
Subarnarekha Sinha
David L. Dill
Ravindra Majeti
Daniel Thomas
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of WO2017083716A2 publication Critical patent/WO2017083716A2/fr
Publication of WO2017083716A3 publication Critical patent/WO2017083716A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés analytiques et des systèmes pour déterminer les partenaires létaux synthétiques (LS) d'un gène d'intérêt. L'identification d'un ou un ensemble de candidats partenaires LS associés à une mutation dans un gène d'intérêt permet de développer des thérapies ciblées pour une oncologie de précision, fournit des cibles pour le criblage de médicaments, permet de nouvelles application pour des médicaments existants et pour des applications théranostiques. Un partenaire LS pour une mutation récurrente dans IDH1 est identifié, laquelle mutation de IDH1 peut être présente dans des tumeurs malignes hématologiques, telles que des cellules de leucémie myéloïde aiguë (LMA) et dans des tumeurs solides.
PCT/US2016/061623 2015-11-13 2016-11-11 Détermination de partenaires létaux synthétiques de modifications spécifiques du cancer et procédés pour les utiliser WO2017083716A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562255195P 2015-11-13 2015-11-13
US62/255,195 2015-11-13

Publications (2)

Publication Number Publication Date
WO2017083716A2 WO2017083716A2 (fr) 2017-05-18
WO2017083716A3 true WO2017083716A3 (fr) 2017-07-13

Family

ID=58695494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/061623 WO2017083716A2 (fr) 2015-11-13 2016-11-11 Détermination de partenaires létaux synthétiques de modifications spécifiques du cancer et procédés pour les utiliser

Country Status (1)

Country Link
WO (1) WO2017083716A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110797080A (zh) * 2019-10-18 2020-02-14 湖南大学 基于跨物种迁移学习预测合成致死基因
CN113362894A (zh) * 2021-06-15 2021-09-07 上海基绪康生物科技有限公司 一种对协同致死的癌症驱动基因进行预测的方法
WO2023022659A1 (fr) * 2021-08-19 2023-02-23 Engine Biosciences Pte. Ltd. Compositions et procédés de génération de létalité synthétique dans des tumeurs
CN114566211B (zh) * 2022-03-14 2024-05-14 杭州师范大学 基于生物网络与机器学习的合成致死基因组合预测系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126840A1 (en) * 2002-12-23 2004-07-01 Affymetrix, Inc. Method, system and computer software for providing genomic ontological data
WO2011144738A1 (fr) * 2010-05-21 2011-11-24 Emergentec Biodevelopment Gmbh Cibles géniques critiques pour une thérapie cytotoxique
WO2014194092A1 (fr) * 2013-05-30 2014-12-04 Memorial Sloan-Kettering Cancer Center Système et procédé pour la prévision automatisée de vulnérabilités dans des échantillons biologiques
WO2015066052A1 (fr) * 2013-10-28 2015-05-07 New York University Procédés, support accessible par ordinateur et systèmes pour modéliser la progression d'une maladie à l'aide de données biomédicales provenant de multiples patients

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126840A1 (en) * 2002-12-23 2004-07-01 Affymetrix, Inc. Method, system and computer software for providing genomic ontological data
WO2011144738A1 (fr) * 2010-05-21 2011-11-24 Emergentec Biodevelopment Gmbh Cibles géniques critiques pour une thérapie cytotoxique
WO2014194092A1 (fr) * 2013-05-30 2014-12-04 Memorial Sloan-Kettering Cancer Center Système et procédé pour la prévision automatisée de vulnérabilités dans des échantillons biologiques
WO2015066052A1 (fr) * 2013-10-28 2015-05-07 New York University Procédés, support accessible par ordinateur et systèmes pour modéliser la progression d'une maladie à l'aide de données biomédicales provenant de multiples patients

Also Published As

Publication number Publication date
WO2017083716A2 (fr) 2017-05-18

Similar Documents

Publication Publication Date Title
WO2017083716A3 (fr) Détermination de partenaires létaux synthétiques de modifications spécifiques du cancer et procédés pour les utiliser
WO2020023420A3 (fr) Procédés et systèmes pour ajuster la charge de mutation de tumorale par fraction et couverture tumorales
WO2014201435A8 (fr) Procédé de criblage d'entités biochimiques candidates ciblant une entité biochimique cible
EP4282405A3 (fr) Détection de biomarqueurs du cancer à l'aide de nanoparticules
Lauschke et al. Pharmacoepigenetics and toxicoepigenetics: novel mechanistic insights and therapeutic opportunities
MX2021016027A (es) Ensayos y metodos para deteccion de acidos nucleicos.
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
WO2016046640A3 (fr) Procédés de prédiction de la réactivité à un médicament
WO2018187496A3 (fr) Profilage de protéine à base de plasma pour le pronostic précoce du cancer du poumon
BR112017025297A2 (pt) anticorpos anti-gitr para diagnóstico do câncer
MX2016016902A (es) Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
Amorim et al. The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles
Quintero et al. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer
Fox et al. Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells
D'Souza-Schorey et al. Biology and proteomics of extracellular vesicles: harnessing their clinical potential
Du et al. Prognostic value of high CXCR4 expression in renal cell carcinoma: a system review and meta‐analysis
WO2018046770A3 (fr) Marqueur et cible en tant que variable de diagnostic et cible pour le traitement du cancer métastatique
Hanover et al. Integration of cancer-related genetic landscape of Eph receptors and ephrins with proteomics identifies a crosstalk between EPHB6 and EGFR
Lahiri et al. MALDI imaging mass spectrometry as a novel tool for detecting histone modifications in clinical tissue samples
Tadmor et al. The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis
Pulley et al. Motivation for launching a cancer metastasis inhibition (CMI) program
BR112015015050A2 (pt) Métodos para diagnosticar melanoma e carcinoma da célula basal em um indivíduo e para determinar probabilidade de responder ao tratamento com um inibidor de quinase em um indivíduo com melanoma ou carcinoma da célula basal, e, uso de um inibidor do ddr2
Ghosh et al. Central role of ubiquitination in genome maintenance: DNA replication and damage repair
Weiskirchen Intratumor heterogeneity, variability and plasticity: questioning the current concepts in classification and treatment of hepatocellular carcinoma
Kearney et al. 8-Chloroadenosine sensitivity in renal cell carcinoma is associated with AMPK activation and mTOR pathway inhibition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16865127

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16865127

Country of ref document: EP

Kind code of ref document: A2